INTRODUCTION
 Regulatory Affairs departments are growing within companies & is constantly evolving and growing and is the one which is least impacted during the Acquisition and Merger, and also during recession. Global harmonization in standards has led to consistent approach in regulatory submissions and hence its review.
 Systematic formulation development acts as a back bone for any dossier preparation in export registration  There are different requirements in different countries for registration It is difficult for any company to develop product for each region Therefore; we need to consider majority of requirements during technical data submission which will help in export registration.
 Regions, but all are national registrations in these countries.
 Enormous diversity of regulatory requirements are there, however, harmonisation occurs as clusters e.g.
ASEAN, Gulf
Global Market is divided into: 
Justification for Impurity Limits
The following factors to be considered while fixing the specification limits
• API impurity limits data (COA)
• Check ICH requirements.
• Check pharmacopoeial limits, if any.
• API stability data.
• Finished product stability data etc.
Manufacturing Formula & Process
 Manufacturing Formula  If a test is based on a compendia monograph, a copy of the monograph + any methods referenced in the monograph must be submitted.
 Details of any specifications and test methods additional to those in the Pharmacopoeia must be submitted.
Method Validations for FP and API
 In few countries Validation of analytical methods is still not mandatory if the Pharmacopoeial method is followed.
 Non-Compendial method needs to be validated if required by the Agency.
Stability Data and Stability Protocol
 Ability of pharmaceutical product to retain its property within specified limits throughout shelf-life  The stability programme includes sample size, test interval, storage conditions, specific methods and container closure system  Stability studies should include testing of those attributes of the Finished product that are susceptible to change during storage and are likely to influence quality, safety and efficacy  Testing should cover, the physical, chemical, biological and microbiological attributes, preservative content and functionality tests ( e.g. Nebulizer).
 Microbial limits at release and end of shelf life. Dissolution limit should be same as for release.  API used shall preferably be of different batches.  Stability to be performed on each individual strength & container size of drug product, unless bracketing or matrixing is applied.  In conclusion Shelf life should be proposed / concluded including the storage condition.  Generally 3 batches (2 pilots, 1 smaller) data is required to be submitted.  A pilot scale batch is generally, one tenth of a full production scale or 100,000 units, whichever is larger 
